Ankyrin repeat domain 28 (ANKRD28) has been confirmed as an oncogene in acute myeloid leukemia (AML).[11, 12] Analogously, super‐enhancers‐regulated ANKRD28 correlates with poor prognosis in patients with germinal center B‐cell diffuse large B‐cell lymphoma (GCB‐DLBCL).[13] Despite the evidence in other hematologic neoplasms, the role of ANKRD28, especially its non‐coding DNA regions that served as enhancers, remains unclear in MM. Here, ANKRD28 is linked to hematopoietic and lymphoid system neoplasm.